Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Results 1 - 20 of 229 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar SapphireSeas (76.07) Submitted: 6/1/2015 2:29:55 PM : Outperform Start Price: $66.31 BMY Score: +4.07

A leader in cardiovascular R&D and treatments, and now coming on strong with two immunotherapy candidates - ipilimumab and nivolumab - which show tremendous promise.

Recs

0
Member Avatar andrewtraylor (73.46) Submitted: 5/8/2015 6:39:40 PM : Outperform Start Price: $66.62 BMY Score: +3.30

M.I.T.B.- Money in the Bank

Recs

0
Member Avatar hutchcraft2 (53.25) Submitted: 3/18/2015 4:32:47 PM : Outperform Start Price: $67.60 BMY Score: +1.08

Well managed with strong product line.

Recs

0
Member Avatar Defshark82 (78.76) Submitted: 12/31/2014 11:44:21 AM : Outperform Start Price: $59.11 BMY Score: +14.46

Tracking JPM top pick

Recs

0
Member Avatar foolmelgoner (81.15) Submitted: 12/15/2014 8:49:32 PM : Outperform Start Price: $57.29 BMY Score: +13.39

Solid pipeline, good management

Recs

0
Member Avatar AnsgarJohn (98.42) Submitted: 11/16/2014 8:54:06 AM : Underperform Start Price: $56.73 BMY Score: -17.25

Bristol-Myers a favorite of Jima Cramer and Fools, but seems to be getting ahead of itself. PE almost 40, not much growth. End ASAP http://www.gurufocus.com/stock/BMY&summary

Recs

0
Member Avatar mrgekko (50.85) Submitted: 11/7/2014 4:56:31 AM : Outperform Start Price: $57.25 BMY Score: +15.83

some great phase 3 drugs and in the right areas

Recs

0
Member Avatar JeffRossMD (< 20) Submitted: 10/30/2014 12:44:24 PM : Outperform Start Price: $57.25 BMY Score: +13.64

The biotech space is just heating up as new technologies are revolutionizing cancer and chronic disease processes.

Recs

0
Member Avatar mikeayu (< 20) Submitted: 10/14/2014 7:06:01 PM : Outperform Start Price: $47.52 BMY Score: +30.03

Huge upside from cancel drugs.

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 10/1/2014 2:23:35 PM : Outperform Start Price: $49.64 BMY Score: +25.85

Div. (Yield) $1.44 (2.8%)

Recs

0
Member Avatar Herbstmd (58.70) Submitted: 8/22/2014 11:55:42 AM : Outperform Start Price: $48.82 BMY Score: +34.19

Developing great new cancer drugs called PD1, which may revolutionize cancer therapy.

Recs

0
Member Avatar Kenji94 (61.18) Submitted: 8/19/2014 1:29:19 AM : Underperform Start Price: $48.94 BMY Score: -33.08

There is a disconnection between price and fundamentals. I would like to own the company, but not at this price.

Recs

0
Member Avatar hydn (< 20) Submitted: 5/16/2014 10:28:57 AM : Outperform Start Price: $47.25 BMY Score: +31.96

Solid demand for ever improving products.

Recs

0
Member Avatar Johnybe (60.80) Submitted: 5/14/2014 9:46:28 PM : Outperform Start Price: $47.95 BMY Score: +30.83

strong player in this sector

Recs

0
Member Avatar DRGRNR (< 20) Submitted: 4/15/2014 7:52:17 PM : Outperform Start Price: $46.90 BMY Score: +32.11

I've owned BMY for 30 years, always a strong performer.

Recs

0
Member Avatar bassnman45 (36.42) Submitted: 1/2/2014 9:30:25 PM : Outperform Start Price: $20.50 BMY Score: +159.00

buy, hold long term and monitor

Recs

1
Member Avatar johnclanaro (< 20) Submitted: 10/28/2013 3:54:27 PM : Outperform Start Price: $49.80 BMY Score: +17.85

recent upgrade. good pipeline.

Recs

1
Member Avatar gilmomp1 (61.61) Submitted: 10/16/2013 9:38:21 PM : Outperform Start Price: $46.41 BMY Score: +24.42

I bought 100 shares of this company pre 1995 and now own 188 shares by reinvesting my dividends. Now that I'm nearing retirement that dividend looks pretty good!

Recs

1
Member Avatar nancytroi (< 20) Submitted: 10/2/2013 11:43:34 AM : Outperform Start Price: $44.59 BMY Score: +28.40

Continues finding new drugs to fight cancers

Recs

0
Member Avatar lg7691 (30.29) Submitted: 7/21/2013 1:34:10 PM : Outperform Start Price: $41.97 BMY Score: +38.40

7/21/13 44.19 drug stock

Featured Broker Partners


Advertisement